Christos Paliompeis

Director, Clinical Science @Summit Therapeutics, Inc.

Cambridge, GB
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jan 2026 — Present

Director, Clinical Science @Summit Therapeutics, Inc.

View department →

Oxford, GB

Clinical Scientist — contributing to late-stage global oncology clinical development.• NCT06••••14: Randomized, double-blind, multiregional Phase study of ivonescimab versus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer in patients with high PD-L1 expression (HARMONi-7).• NCT05••••08: Randomized, double-blind, multiregional Phase study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy as first-line treatment for metastatic non-small cell lung cancer (HARMONi-3).

EDUCATION

2003

University of Glasgow

Bachelor of Science Honours - BSc Hons, Molecular and Cellular Biology

2015

Imperial College London

Master of Research - MRes, Clinical Research Design & Management

2005

Imperial College London

Master of Science - MS, Molecular Medicine

2021

University of Oxford

Master of Science - MS, Experimental and Translational Therapeutics

2020

King's College London

Master of Science - MS, Clinical Pharmacology

ABOUT CHRISTOS PALIOMPEIS

I am a seasoned clinical scientist with over 17 years of experience in the pharmaceutical…

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.